Antimisiaris Sophia

Laboratory of Pharmaceutical Technology, Dept. of Pharmacy, University of Patras, Patras, Greece 
Institute of Chemical Engineering, FORTH, Patras, Greece 

SGA received her B.Pharm (1984) and Ph.D in Pharmaceutics (1988) from Athens University, Greece. She worked as a Post-doc research assistant in the School of Pharmacy of the University of South California, Los Angeles for 2 years (1989-1990), and then became a Lecturer of Pharmaceutical Technology in the University of Patras in Greece, where she became the head of the Laboratory of Pharmaceutical Technology (from 2002) and a full Professor in 2009. She worked on Liposome Technologies for Advanced Drug Delivery applications as a Visiting Professor in the School of Pharmacy, University of London, group of Prof. Gregory Gregoriadis (1992- 1993). From 2006, she is a collaborating member of the Institute of Chemical Engineering of the Foundation of Research and Technology Hellas (FORTH), the largest research Institute in Greece.  SGA’s research group focuses on the development of liposomal nanomedicines for controlled and/or targeted drug delivery. She has received funding from National and European sources (FP6, INTERREG, Marie Curie, FP7, H2020), as well as Industry. She is the main author of more than 120 peer-reviewed papers and more than 25 book chapters and review articles. She has mentored 29 MSc students and 15 PhD Thesis and participated in the advisory committees of more than 50 Post-graduate degrees in Greece and other countries. She is a member of AAPS, CRS (& CRS-Greek Chapter), ILS and other National and International Scientific Societies, and inventor of 5 Greek, 1 European, 1 US and 1 World patent. 

Title of Talk 
Smart Bone Regeneration (SBR): A H2020 Programme 

The EU’s Horizon 2020 research and innovation programme (grant agreement No 874896), Smart Bone Regeneration (SBR) aims to improve treatment options for patients with large bone defects. By combining a smart implant with innovative tissue-engineering methods, the project will develop a minimally invasive technique designed to complement existing clinical practices. 

SBR will address three major challenges that have limited the treatment of large bone defects in the past: 

  • The design and fabrication of a smart biodegradable membrane that possesses bone guiding regeneration properties. 
  • The implementation of a novel, hybrid approach towards intelligent bone regeneration in large bone defects. 
  • The capability to offer new treatment capabilities of such challenging clinical conditions as large bone defects, non-unions and bone voids. 

Acknowledgement: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874896